The findings include failures in assay testing in all six entries, with the 2.5 mg batch also failing sterility testing. Synopsis: The CDSCO’s September 2026 drug-quality alert flags six batches of Eli Lilly’s Mounjaro KwikPen across all six strengths sold in India, with assay failures recorded for every batch.